Novel Lateral Flow-Based Assay for Simple and Visual Detection of SARS-CoV-2 Mutations

Identification of the main SARS-CoV-2 variants in real time is of interest to control the virus and to rapidly devise appropriate public health responses. The RT-qPCR is currently considered to be the reference method to screen SARS-CoV-2 mutations, but it has some limitations. The multiplexing capa...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in cellular and infection microbiology 2022-07, Vol.12, p.902914-902914
Main Authors: Gomez-Martinez, Julien, Henry, Steven, Tuaillon, Edouard, Van de Perre, Philippe, Fournier-Wirth, Chantal, Foulongne, Vincent, Brès, Jean-Charles
Format: Article
Language:English
Subjects:
Bioengineering
Cellular and Infection Microbiology
DNA microarray
lateral flow strip (LFS)
Life Sciences
Microbiology and Parasitology
molecular diagnostic
SARS-CoV-2 mutations
Virology
visual detection
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Identification of the main SARS-CoV-2 variants in real time is of interest to control the virus and to rapidly devise appropriate public health responses. The RT-qPCR is currently considered to be the reference method to screen SARS-CoV-2 mutations, but it has some limitations. The multiplexing capability is limited when the number of markers to detect increases. Moreover, the performance of this allele-specific method may be impacted in the presence of new mutations. Herein, we present a proof-of-concept study of a simple molecular assay to detect key SARS-CoV-2 mutations. The innovative features of the assay are the multiplex asymmetric one-step RT-PCR amplification covering different regions of SARS-CoV-2 S gene and the visual detection of mutations on a lateral flow DNA microarray. Three kits (Kit 1: N501Y, E484K; Kit 2: L452R, E484K/Q; Kit 3: K417N, L452R, E484K/Q/A) were developed to match recommendations for surveillance of SARS-CoV-2 variants between January and December 2021. The clinical performance was assessed using RNA extracts from 113 SARS-CoV-2-positive samples with cycle thresholds
ISSN:2235-2988
2235-2988
DOI:10.3389/fcimb.2022.902914